Showing results (101-110 of 114) with videos related to

Sort By:
Pageof 12
Journal of Medicinal Chemistry|October 13, 2006
Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteinsGuoping Wang, Zaneta Nikolovska-Coleska, Chao-Yie Yang, et al.
Nature Cell Biology|January 14, 2022
PKCβII phosphorylates ACSL4 to amplify lipid peroxidation to induce ferroptosisHai-Liang Zhang, Bing-Xin Hu, Zhi-Ling Li, et al.
Cellular & Molecular Immunology|December 7, 2023
The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activationFan Luo, Han Li, Wenjuan Ma, et al.
Signal Transduction and Targeted Therapy|November 3, 2025
Olverembatinib, a multikinase inhibitor that modulates lipid metabolism, in advanced succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 1b study and translational researchHai-Bo Qiu, Zhiyan Liang, Jing Yang, et al.
Theranostics|March 21, 2018
XIAP Limits Autophagic Degradation of Sox2 and Is A Therapeutic Target in Nasopharyngeal Carcinoma Stem CellsJiao Ji, Yan Yu, Zhi-Ling Li, et al.
Journal of Hematology & Oncology|August 18, 2022
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trialQian Jiang, Zongru Li, Yazhen Qin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2023
Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label TrialSikander Ailawadhi, Zi Chen, Bo Huang, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 5, 2008
Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibitionSanjeev Shangary, Dongguang Qin, Donna McEachern, et al.
Cancer Letters|July 19, 2016
A novel Smac mimetic APG-1387 demonstrates potent antitumor activity in nasopharyngeal carcinoma cells by inducing apoptosisNing Li, Lin Feng, Hui-Qiong Han, et al.
JAMA Oncology|November 21, 2024
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical TrialElias Jabbour, Vivian G Oehler, Paul B Koller, et al.
Pageof 12